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were extracted alongside whether the priority status, pre- or post-NOC pCODR 
submission, and if the drug was a first submission or line extension. Statistical 
comparisons were made using Student’s t-test. RESULTS: 32 pCODR reports were 
extracted with an average of 203 days between pCODR submission to recom-
mendation, with a wide variation between different drugs (range: 119-329 days, 
median: 198). There was no significant variation in the average time required 
for pCODR decision-making based on priority status (prioritisation granted: 232 
days, [n= 3]; prioritisation not granted: 202 days, [n= 29]; p= 0.17). There was also no 
significant variation in time required for line extensions versus first submissions 
(line extension: 197 days, [n= 9]; first submissions: 205 days, [n= 23]; p= 0.34). pCODR 
decision-making time did also not significantly vary between those submitted 
prior- versus post-regulatory approval (pre-NOC: 213 days, [n= 18]; post-NOC: 191 
days, [n= 14]; p= 0.26). CONCLUSIONS: Although there are some wide variations 
in the time required for pCODR to issue recommendations between different 
drugs, this did not correlate with prioritisation status, whether the drug was a 
first submission or line extension, or if a submission was made pre-or post-NOC 
in a statistically significant manner. However, the small sample sizes may have 
precluded finding statistical significances. Further research is needed to define 
the key factors underlying this variation.
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OBJECTIVES: Recently, the use of OC and HT either as monotherapy, or added to/
replacing intravenous chemotherapy (CT) drugs for the treatment of different malig-
nancies have increased in Brazil. Federal law number 12880/2013 was one of the 
hallmarks of oncologic drug access as it established the patients’ right to OC coverage 
in the Brazilian Private Healthcare System (PHS), whereas before only the payment 
of intravenous drugs was covered. The aim of this study is to evaluate real-world 
data on OC access one year after the publication of law 12880/2013. METHODS: All 
chemotherapy requests submitted between January 2013 and December 2014, regard-
less of cancer type, were extracted from Evidencias - Kantar Health private market 
administrative claims database. Subsequently, we evaluated all OC/HT requests and 
classified them as approved or denied for coverage, depending on the appropriateness 
of drug indication. The approved ones were assessed and compared monthly and 
yearly in order to evaluate the difference of utilization before and after the publication 
of law 12880/2013. RESULTS: A total of 17,512 requests were individually evaluated. 
There were 2,504 OC and HT (2,228 approved, 276 unapproved) requests. Before law 
12880/2013 was implemented (in January 1st 2014), the total number of requests 
for OC and HT were 332 and 78, respectively. After the mandatory coverage of these 
therapies, there were 622 OC and 968 HT requests (an increase of 87.3% and 1,141%, 
respectively). CONCLUSIONS: A significant increase was observed in the number 
of requests for hormonal therapies such as tamoxifen and anastrozole in 2014. The 
increase in number of hormonal therapy requests was more marked then that of OC.
PCN158
determINaNts for guIdelINe aPProPrIate Care amoNg elderly WomeN 
WIth stage I-III Breast CaNCer IN a seer-medICare PoPulatIoN
LeMasters T.J., Madhavan S.S., Sambamoorthi U., Kelly K., Hazard H., Long D.
West Virginia University, Morgantown, WV, USA
OBJECTIVES: Evidenced-based guidelines for the treatment of breast cancer have been 
put forth by agencies such as the National Comprehensive Cancer Network (NCCN). 
Yet, even with specific guidelines, gaps in the receipt of appropriate care exist. This 
study examined factors associated with receipt of appropriate vs. inappropriate treat-
ment among elderly women with breast cancer in the U.S. METHODS: A sample of 
11,948 women age > 66 with pathologically staged I, II, and III breast cancer diagnosed 
from 2004 to 2006 were selected from the SEER-Medicare linked dataset. Algorithms 
based on clinical cancer characteristics and types of treatments and testing received 
were used to determine appropriateness of care (yes vs. no). Logistic regression 
models were used to examine the relationship between appropriateness of care and 
various independent factors. RESULTS: Less than 32% of elderly women received 
guideline appropriate care. The likelihood of receiving appropriate care decreased for 
women with increasing age (> 80 vs. 66-69) (AOR, 0.23; 95%CI, 0.20-0.27), comorbidity 
(> 2 vs. 0) (AOR, 0.85; 95%CI, 0.75-0.97), stage (III vs. I) (AOR, 0.50; 95%CI, 0.40-0.61) and 
(II vs. I) (AOR, 0.33; 95%CI, 0.28-0.38), and were of non-white race vs. white (AOR, 0.83; 
95%CI, 0.73-0.96). Women with node negative cancer, poorly differentiated tumors, 
borderline/unknown tumor receptors were also less likely to receive appropriate care. 
Yet, the likelihood of appropriate care was increased for women who saw both a gen-
eral and oncology surgeon vs. general surgeon only (AOR, 1.35; 95%CI, 1.19-1.53), lived 
in areas of higher income vs. lower (AOR, 1.15; 95%CI, 1.01-1.30), and higher education 
vs. lower (AOR, 1.15; 95%CI, 1.03-1.29). CONCLUSIONS: Irrespective of guidelines, less 
complex patients with greater resources are more likely to receive appropriate care. 
Better efforts should be made for all elderly women with breast cancer to receive 
appropriate care regardless of their age, health, or resources.
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OBJECTIVES: Many elderly women with early-stage breast cancer (BC) receive mastec-
tomy when breast-conserving surgery (BCS) plus radiation therapy (RT) is an option, 
or do not receive recommended RT following BCS. This study examined associations 
with primary treatment (BCS+RT, mastectomy, or BCS without RT) for early-stage BC 
among elderly women. METHODS: A sample of 26,106 women age > 66 diagnosed 
respectively. Stage distributions indicated the greatest prevalence with stage IV dis-
ease: 39%, 73%, and 68% among breast, colon, and lung cancers patients. Pathology 
results among lung cancer patients demonstrated 78% and 22% with non-small 
cell and small cell cancers, respectively. 36% of breast cancer patients were HER2 
positive, 29% of lung cancer patients were detected with EGFR mutation, and 39% of 
colon cancer patients were detected with KRAS mutation among those reporting test 
results. The majority of patients in each cancer group (81.7%-90.3%) had an ECOG 
performance status of 0 or 1. CONCLUSIONS: Given the recent implementation of 
the CCQP, this analysis provides valuable initial insight into the demographic and 
clinical characteristics of patients within participating practices. This integrated 
data provides a comprehensive picture for commercially-insured oncology patients 
and baseline data for future program evaluation.
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OBJECTIVES: Medicare contracting reform resulted in the replacement of Medicare 
Part A/B claims processors, known as fiscal intermediaries (FIs) and carriers, with 
Medicare Administrative Contractors (MACs). This study examines the implemen-
tation of MACs on the receipt of chemotherapy and biologic agents for the treat-
ment of metastatic colon cancer (mCC). METHODS: This retrospective study used 
Surveillance, Epidemiology and End Results (SEER) Medicare data to examine the 
receipt of National Comprehensive Cancer Network (NCCN) approved chemotherapy 
and biologic agents by elderly patients with mCC who were diagnosed between 2006 
and 2009 and followed through 2011. The odds ratios associated with the interac-
tion between pre/post MAC implementation and whether the implemented MAC 
had previously been a FI/carrier in the region were estimated using a generalized 
linear mixed model with a random effect for SEER-region. Age, race, marital status, 
gender, Medicaid buy-in, poor-performance status, the Charlson Comorbidity Index 
and year of diagnosis were covariates in the model. RESULTS: The final sample 
included 9,509 patients. 4,034 (41%) received NCCN-approved chemotherapy at any 
time after diagnosis and 2202 (22%) received an NCCN-approved biologic at any time 
after diagnosis. Individuals diagnosed post-implementation in a region where the 
MAC was not previously a FI/carrier had no reduction in the odds of receiving either 
NCCN-approved chemotherapy (odds ratio [OR]: 0.95, 95% confidence interval [CI]: 
0.69–1.29) or NCCN-approved biologics (OR: 1.17, 95% CI: 0.85–1.61) at any time after 
cancer diagnosis as compared with patients diagnosed in the post period where the 
MAC was previously a FI/carrier. CONCLUSIONS: Evidence was not found to support 
the hypothesis that MAC implementation impacted the odds of a Medicare mCC 
patient receiving NCCN-approved chemotherapy or biologic agents. Future research 
should focus on examining the impact of Medicare contracting reform on specific 
treatment lines in combination with biologic use.
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OBJECTIVES: The main objective of this study is to identify the sequences followed 
and delays encountered by each anticancer product between the country of origin 
and the delivery point at the main anti-cancer center in Algeria the CPMC. A second 
objective is to evaluate the effects of the introduction of the special procedure called 
“temporary authorization of a use” (TAU). METHODS: A sample of Oncology drugs 
was determined for the period 1999–2013. These oncology products were approved 
by the European medicines agency. A sample of 60 products was selected. The main 
sequences studied were: Date of market authorization by EMA and Algeria, date of 
first purchase by the central pharmacy for hospitals (responsible for procurement of 
inpatients drugs) and date of registration of the drug on the list of oncology products 
used by the CPMC. The sequences and time periods have been identified but also 
analyzed using a regression model. RESULTS: The analysis shows that 30% drugs 
have been registered in Algeria and the overall mean time required before patients 
access was 32 months: Between 1999-2007 (pre-ATU) it was 48 months and 25 month 
for 2007-2012 (post- ATU). The high product prices have been felt as a serious obstacle 
to large introduction and access, moreover we identified a significant differences 
in term of the early access between the companies implemented in the local mar-
ket and the companies who set up a liaison offices in Algeria. CONCLUSIONS: This 
study identified some of the main factors affecting the introduction and diffusion of 
oncology drugs from between the European market and the main delivery point to 
patients in Algeria. Strengthening national capacities and mechanisms to evaluate 
real performance and cost-effectiveness should be more than ever on the agenda 
of the national health authorities as oncology drugs is representing almost half of 
budget for pharmaceuticals.
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OBJECTIVES: The pan-Canadian Oncology Drug Review (pCODR) was established 
in 2010 to appraise oncologics to help guide provincial decision-making. pCODR 
prioritises reviews for new drugs that offer potential substantial improvements 
on significant outcomes and will also accept submissions prior to a Notification 
of Compliance (NOC) of regulatory approval being granted. This research aims to 
define the time required for pCODR to issue recommendations and what factors 
affect the decision-making time. METHODS: All published pCODR reports were 
extracted up to 30 September 2014 and the dates of submission and notification 
